mt-vc-funding-2007.gifVenture-capital funding continued to rise in the fourth quarter, continuing a recent boom despite economic jitters sown by the subprime-mortgage financial mess.

VCs tossed $7 billion at startups in the fourth quarter, a substantial 12 percent rise over the same quarter last year, according to data published by PricewaterhouseCoopers, the National Venture Capital Association and Thomson Financial. Fourth-quarter funding slumped a bit compared to the average of $7.5 billion raised in each of the first three three quarters, although it’s difficult to say at this point whether that reflects early economic nervousness or simply a seasonal Q4 slowdown in the deal flow.

Overall 2007 investment in venture firms also rose 11 percent to $29.4 billion, a six-year high. (Of course, the 2007 figure is still dwarfed by the staggering $105.1 billion that flowed into Web and genomics startups in 2000 at the height of the bubble.)

Biotech companies led in overall financing, raising $1.29 billion in the quarter — a four percent rise over last year — which let the sector narrowly edge out software, which pulled in $1.27 billion. The two sectors are effectively tied at this point, and have traded the first-place slot back and forth since mid-2006.

Medical devices also had a strong quarter with $900.7 million in funding, nearly a 35 percent increase over last year. Two of the top ten financings in the quarter were the medical-device firms Evalve , a maker of heart-valve repair kits, and Zosano Pharma, which is developing needle-free patches that deliver drugs through the skin. These companies raised $60 million and $45 million, respectively. Biotech’s sole representative in the top ten deals was Ambit Biosciences, which received $49.3 million to support its development of new cancer drugs.

Cleantech funding almost doubled over the previous year, reaching $468.7 million in the quarter — apparently a record quarter. Major deals included EverPower Renewables, which raised $55 million for wind-power farms and Serious Materials, which drew $50 million for green building materials.

It’s notable that the funding directed to early stage companies has continued to edge up over the past six years, reaching $6.3 billion in 2007. That comes against a backdrop, however, in which expansion- or late-stage companies are absorbing an increasing portion of all funding. (See the second chart at the bottom of this post.)

For a closer look, check out these lists of the top ten deals in the fourth quarter and all of 2007 (Excel spreadsheet files). If you prefer, here is a slide show of Q4 and 2007 trends (PDF), and here are the raw numbers (Excel spreadsheet).

A competing set of VC-funding numbers from Dow Jones VentureOne and Ernst & Young aren’t due out until Tuesday, but I’ll poke through them then to see if there’s any news worth reporting. Meanwhile, here are some more graphics for your weekend enjoyment.



VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.